CVS Caremark is restoring Zepbound on October 1, 2026, with $25 copays for eligible members — but employers can still opt out. Here’s the timeline, what it really costs, and the compounded-tirzepatide math if you can’t wait or aren’t covered.
CVS Caremark will cover Zepbound again starting October 1, 2026, as a co-preferred option on its standard commercial formulary (about 25–30 million members), reversing the July 2025 exclusion. The oral GLP-1 Foundayo was added June 1, 2026. Eligible commercially insured members can expect roughly $25/month once covered; Medicare Part D members can pay a flat $50/month for Wegovy or Zepbound through the GLP-1 Bridge program beginning July 1, 2026. The catch: “co-preferred” doesn’t guarantee your plan pays — employers can opt out. If you’re not covered, compounded tirzepatide is the same molecule at a fraction of cash price, and a flat-rate provider such as NexLife runs $186/month.
In July 2025, CVS Caremark became the only major pharmacy benefit manager to drop Zepbound while keeping Novo Nordisk’s Wegovy, after a formulary deal between the two. Patients pushed back — many had better results on tirzepatide — and a class-action lawsuit followed. On May 28, 2026, CVS reversed course. Here is the full timeline.
| Date | What happens |
|---|---|
| Jul 1, 2025 | CVS Caremark drops Zepbound from Standard, Advanced Control, and Value formularies; prefers Wegovy. |
| Sep 2025 | Patients file a class-action lawsuit over the exclusion (still active). |
| Jun 1, 2026 | Foundayo (oral orforglipron) added to coverage. |
| Jul 1, 2026 | Medicare GLP-1 Bridge launches: flat $50/mo for Wegovy or Zepbound (through end of 2027). |
| Oct 1, 2026 | Zepbound returns as a co-preferred GLP-1 on the standard commercial formulary. |
The headline numbers are good — if your plan covers GLP-1s for weight loss. Eligible commercially insured members can expect about $25/month for Zepbound or Foundayo once coverage is active. Medicare Part D members get a flat $50/month for Wegovy or Zepbound via the GLP-1 Bridge. But being on CVS Caremark’s template is not the same as your specific plan paying for it: self-funded employers can still exclude weight-loss GLP-1s entirely. The other two large PBMs, Express Scripts and OptumRx, already cover Zepbound.
If covered after Oct 1, a $25 copay wins. If you’re not covered, a flat compounded plan is the cheapest cash route to the same molecule.
For a CVS Caremark member, the cost of staying on tirzepatide has been a cliff: a manageable copay in early 2025, full cash price through the exclusion, then back down to about $25 once October arrives. Plotted over time, that volatility is the whole story — and it’s why many people bridged the gap with compounded tirzepatide, which held one flat price the entire time.
Brand Zepbound copay vs. a flat compounded plan through the coverage gap.
The right answer depends on three things: whether your plan covers weight-loss GLP-1s at all, how long you’re willing to wait, and whether you’re already paying cash. Use this framework.
| Your situation | Best move |
|---|---|
| Covered for GLP-1s, currently on Wegovy | If tirzepatide worked better for you, ask about switching back to Zepbound after Oct 1 — the $25 copay makes it easy. |
| On Medicare | Mark July 1: the $50 GLP-1 Bridge copay is likely your cheapest legitimate path. |
| Wegovy isn’t tolerated/effective | Request a formulary exception now; document medical necessity. |
| Plan excludes weight-loss GLP-1s, or you’re uninsured | The formulary news doesn’t help you. Compounded tirzepatide is the same molecule at a fraction of cash price — a flat-rate provider like NexLife ($186/mo) is usually the lowest predictable cost. |
| Want to start today, can’t wait until October | Compounded now, then reassess after Oct 1 once your plan’s coverage is confirmed. |
The CVS reversal is a signal about where the whole GLP-1 market is heading in 2026. Payers spent the year fighting the cost of a drug class millions of people want, and the fixes arriving now — manufacturer copay deals, the Medicare GLP-1 Bridge, a new oral option in Foundayo, and Zepbound’s return — all target the same bottleneck: coverage, not clinical evidence, is the biggest reason people stop these medications. For patients, the practical consequence is that the cheapest path keeps moving. A year ago, a CVS Caremark member’s best option was often to switch drugs or pay cash; after October 1 it may be a $25 copay; and for anyone whose plan won’t cover weight-loss GLP-1s at all, compounded tirzepatide remains the only sub-$200 route to the same molecule. Two takeaways follow. First, re-check your options every few months — the numbers that define “cheapest” change faster in this category than almost anywhere else in medicine. Second, if you do bridge a coverage gap with a compounded provider, choose one whose price won’t move while you’re on it, so a coverage decision you don’t control isn’t compounded by a pricing surprise you also don’t control. Predictability is worth more during uncertainty, not less.
Compounded tirzepatide contains the same active ingredient as Zepbound but is prepared by a licensed compounding pharmacy rather than manufactured by Lilly. For a cash-pay patient, it is the only route to tirzepatide under roughly $200/month. The median runs near $199, and NexLife publishes a flat $186/month that stays the same across the full 2.5–15 mg dose range, with named 503A and 503B pharmacy partners, included provider visits and shipping, and LegitScript certification. It is not FDA-approved, and it is not the lowest possible sticker — but among transparent, dose-flat providers it is the lowest predictable cost we track. If your plan covers Zepbound after October, a $25 copay beats it; if it doesn’t, this is your floor. See our compounded tirzepatide vs Zepbound and most affordable tirzepatide guides.